Tumour cell‐derived exosomes carrying PD‐L1 have been suggested to contribute to malignant immunosuppression, but are often associated with the clinical benefits of compensatory immune checkpoint targeted therapies (Chen et al., 2018; Poggio et al., 2019; Ricklefs et al., 2018). Here, CD274 is linked to neoplasm.